Abstract:
BACKGROUND:Several studies have previously demonstrated the survival benefit of both EGFR-TKI treatment and chemotherapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations. The aim of the present study was to clarify the factors influencing the treatment sequence after failure of EGFR-TKI therapy, focusing on the number of organs with metastasis (hereafter, metastatic organs). METHODS:Between January 2010 and December 2016, consecutive patients with EGFR-mutated NSCLC who were started on first-line EGFR-TKI were reviewed. The factors influencing withholding systemic chemotherapy and the post-progression survival (PPS) after failure of EGFR-TKI were investigated. RESULTS:A total of 393 patients were started on first-line EGFR-TKI during the study period. After excluding patients maintained on EGFR-TKI or who received osimertinib targeting secondary EGFR T790M, 297 patients were included in the analysis. Among these, 180 (60.6%) received chemotherapy after failure of EGFR-TKI (TKI-Ct group), while the remaining 117 (39.4%) received no chemotherapy (TKI-only group). Multivariate analysis identified older age (≥75 years: odds ratio [OR] = 0.25, 95% confidence interval [CI]: 0.11-0.43, P < 0.001), poor performance status (PS) (≥2: OR = 0.06, 95% CI: 0.03-0.15, P < 0.001), and three or more metastatic organs (OR = 0.42, 95% CI: 0.22-0.80, P = 0.008) as being significantly associated with withholding of chemotherapy after failure of EGFR-TKI. CONCLUSION:A relatively large number of metastatic organs and a poor PS were associated with the withholding of subsequent chemotherapy after failure of EGFR-TKI in EGFR-mutated NSCLC patients. Further research for patients with such a poor prognosis should be investigated in the future.
journal_name
Thorac Cancerjournal_title
Thoracic cancerauthors
Mizuno T,Horinouchi H,Watanabe S,Sato J,Morita R,Murakami S,Goto Y,Kanda S,Fujiwara Y,Yamamoto N,Ohe Ydoi
10.1111/1759-7714.13360subject
Has Abstractpub_date
2020-04-01 00:00:00pages
1038-1044issue
4eissn
1759-7706issn
1759-7714journal_volume
11pub_type
杂志文章相关文献
Thoracic Cancer文献大全abstract::Atezolizumab was the first immune checkpoint inhibitor (ICI) to be introduced as a first-line treatment option for extensive-stage small cell lung cancer (ES-SCLC), in combination with carboplatin and etoposide (CE) chemotherapy. However, SCLC treatment options after progression to first-line chemotherapy are limited,...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13588
更新日期:2020-09-01 00:00:00
abstract:BACKGROUND:Our recent studies have indicated that miR-153-3p is downregulated in the esophageal squamous cell carcinoma (ESCC) cell lines and tissues. Upregulation of miR-153-3p was found to inhibit migration and invasion of ESCC cells. However, whether miR-153-3p regulates the cisplatin sensitivity in ESCC cells remai...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13326
更新日期:2020-03-01 00:00:00
abstract:BACKGROUND:Tumor mutation burden (TMB) is an important determinant and biomarker for response of targeted therapy and prognosis in patients with lung cancer. The present study aimed to determine whether radiomics signature could non-invasively predict the TMB status and driver mutations in patients with resectable earl...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13163
更新日期:2019-10-01 00:00:00
abstract::We examined two cases of primary lung cancer with sebaceous-like clear cells (SLCCs), defined as clear carcinoma cells with microvacuolated cytoplasm and centrally located nuclei, which were selected from among 281 surgical/autopsy cases of lung cancer (2/281, 0.7%). Both cases were higher stage (stage IIA and IIIA), ...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.12004
更新日期:2013-11-01 00:00:00
abstract:BACKGROUND:Breast cancer is the most common cancer among women. Population-based cancer registration data from the National Central Cancer Registry were used to analyze and evaluate the incidence and mortality rates in China in 2013, providing scientific information for cancer prevention and control. METHODS:Pooled da...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12426
更新日期:2017-05-01 00:00:00
abstract:BACKGROUND:In cases of EGFR-tyrosine kinase inhibitor (TKI) failure, re-biopsy may be useful to understand resistance mechanisms and guide further treatment decisions. However, performing re-biopsy is challenging because of several hurdles. We assessed the feasibility of re-biopsy in advanced non-small cell lung cancer...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12762
更新日期:2018-07-01 00:00:00
abstract::Patients undergoing hemodialysis (HD) are frequently elderly with poor performance status and usually cannot withstand chemotherapy because of its toxicities. We report a case of an elderly woman with chronic renal failure undergoing HD who was diagnosed with advanced non-small cell lung cancer and treated with orally...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12263
更新日期:2016-03-01 00:00:00
abstract:BACKGROUND:Accumulated evidence has revealed that the dysregulation of micro ribonucleic acids (miRNAs) may contribute to esophageal squamous cell carcinoma (ESCC). MiR-93, which is a member of the miRNA cluster miR-106b∼25, has been widely studied for its tumor promoting effect on different types of cancers. However, ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12242
更新日期:2015-07-01 00:00:00
abstract:BACKGROUND:The current study aimed to determine the oncological efficacy and surgical safety of multiple pulmonary resections (MPRs) after prior curative surgery for local regional recurrent or second primary lung cancers. METHODS:All cases of lung cancer included in our prospective database between January 2000 and J...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12790
更新日期:2018-08-01 00:00:00
abstract:BACKGROUND:Central airway obstruction related to endobronchial malignancy is one of the most difficult oncological complications and requires efficient palliative intervention. METHODS:Fifty-three consecutive patients with unresectable endobronchial malignancy receiving bronchoscopic cryotherapy as palliative treatmen...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12248
更新日期:2015-11-01 00:00:00
abstract:BACKGROUND:The combination of EGFR tyrosine kinase inhibitors (TKIs) and chemotherapy is thought to increase treatment efficacy in non-small-cell lung cancer (NSCLC). This study investigated the efficacy and potential mechanisms of different combined modes of icotinib plus pemetrexed in EGFR-mutant lung adenocarcinoma ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12818
更新日期:2018-09-01 00:00:00
abstract::Esophageal cancer with a history of distal gastrectomy is a clinical problem. To our knowledge there have been no reports of remnant stomach fed from the left gastroepiploic artery being used in esophageal reconstruction. We, herein, report four cases of esophagogastric reconstruction using remnant stomach with a sing...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12054
更新日期:2014-03-01 00:00:00
abstract:BACKGROUND:Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of non-small cell lung cancer (NSCLC). While rapid progression (RP) has been proposed as a non-negligible pattern of response to ICIs, its definition and related factors remain unclear. This study aimed to develop a clinical definition of ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13370
更新日期:2020-05-01 00:00:00
abstract:BACKGROUND:Uniportal video-assisted thoracoscopic surgery (VATS) is being more widely used in lung cancer, yet reports on its application in pneumonectomies are limited. This study aimed to evaluate the safety and feasibility of uniportal video-assisted thoracoscopic left pneumonectomy for lung cancer. METHODS:A serie...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13728
更新日期:2021-01-06 00:00:00
abstract:BACKGROUND:The aim of this study was to investigate the patterns and influencing factors of local-regional recurrence of lower thoracic esophageal squamous cell carcinoma (TESCC) after curative resection and to delineate the clinical target volume (CTV) of postoperative radiotherapy (PORT). METHODS:From January 2009 t...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12499
更新日期:2017-11-01 00:00:00
abstract:BACKGROUND:Approximately 8.3-15.9% of patients with clinical stage I non-small cell lung cancer are subsequently shown to have lymph node metastasis. However, the clinical characteristics of patients with lymph node metastasis in China are not fully understood. METHODS:This is a multicenter retrospective analysis of p...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12970
更新日期:2019-03-01 00:00:00
abstract:BACKGROUND: The optimal strategy was not established for patients who initially responded to gefitinib although re-administration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been proven to be an option. Gefitinib and erlotinib were compared as salvage treatment after gefitinib fail...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/j.1759-7714.2012.00152.x
更新日期:2013-05-01 00:00:00
abstract:BACKGROUND:Approximately 15% of lung cancer patients are diagnosed in early stages. Microscopic proof of disease cannot always be obtained because of comorbidity or reluctance to undergo invasive diagnostic procedures. In the current study, survival data of patients with and without pathology are compared. METHODS:One...
journal_title:Thoracic cancer
pub_type: 临床试验,杂志文章
doi:10.1111/1759-7714.12966
更新日期:2019-02-01 00:00:00
abstract::ROS1 rearrangement is a validated therapeutic driver gene in non-small cell lung cancer (NSCLC) and represents a small subset (1-2%) of NSCLC. A total of 17 different fusion partner genes of ROS1 in NSCLC have been reported. The multi-targeted MET/ALK/ROS1 tyrosine kinase inhibitor (TKI) crizotinib has demonstrated re...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.12617
更新日期:2018-05-01 00:00:00
abstract:BACKGROUND:Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) may be necessary for patients with incidental lung cancer during or after coronary intervention. Although EBUS-TBNA is quite safe, the safety in patients who recently received percutaneous coronary intervention (PCI) has not been de...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12846
更新日期:2018-11-01 00:00:00
abstract::In patients with non-small cell lung cancer (NSCLC), stereotactic radiotherapy (SRT) is one of the standard therapies for those suffering with intracranial metastatic NSCLC. Radiation-induced necrosis (RIN) sometimes occurs as the result of the delayed effects of SRT. The magnetic resonance imaging (MRI) of RIN typica...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13494
更新日期:2020-07-01 00:00:00
abstract:BACKGROUND:Many randomized clinical trials have demonstrated that epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are advantageous over standard chemotherapy, either as front-line treatment or as further management of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC). Howev...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12275
更新日期:2016-01-01 00:00:00
abstract:BACKGROUND:Surgery is the standard of care for early stage non-small cell lung cancer (NSCLC). Stereotactic body radiotherapy (SBRT) is another definitive treatment option for those patients who have not been treated surgically. Comparison of approaches is being explored in NSCLC, but has yet to be compared exclusively...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13260
更新日期:2020-02-01 00:00:00
abstract:BACKGROUND:Early diagnosis improves the prognosis for non-small cell lung cancer (NSCLC); therefore, there is a pressing need for effective diagnostic methods for NSCLC. Increasing evidence indicates that serum exosomal micro RNAs (miRNAs) represent promising diagnostic and prognostic markers for multiple cancers. Here...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13644
更新日期:2020-12-01 00:00:00
abstract:BACKGROUND:Esophageal cancer is among the leading cancer types in Inner Mongolia. This study aimed to investigate the incidence and mortality rates of esophageal cancer in 2015 and the trends in these rates in the 2010-2015 period in this region. METHODS:National Colorectal Cancer Roundtable (NCCR) screening methods a...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13552
更新日期:2020-09-01 00:00:00
abstract:BACKGROUND:Scutellarin (SCU), a flavonoid isolated from Erigeron breviscapus (Vant.) Hand.-Mazz., increases autophagy and apoptosis in the adenocarcinoma A549 cell line, which is resistant to cisplatin. However, whether SCU alone has antitumor activity against non-small cell lung cancer (NSCLC) is unknown. METHODS:Cel...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12962
更新日期:2019-03-01 00:00:00
abstract:BACKGROUND:Patients with malignant pleural effusion have a limited life expectancy. An increase in pleural and oncological treatment options and more accurate prognostic evaluation may help individualize treatment strategies. The aim of this study was to identify the prognostic indicators of overall survival (OS) after...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12354
更新日期:2016-07-01 00:00:00
abstract:BACKGROUND:Most non-small cell lung cancer (NSCLC) patients relapse on anaplastic lymphoma kinase-tyrosine kinase inhibitor (ALK-TKI) therapy because of acquired resistance. Rebiopsy is recommended to provide optimal therapy after relapse for some ALK-TKI therapies; however, little clinical data exists on the clinical ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13143
更新日期:2019-09-01 00:00:00
abstract:BACKGROUND:Malignant pleural mesothelioma (MPM) is a rare but aggressive tumor that originates from the pleura and has a poor prognosis. Eligible patients can benefit from surgery, but their survival is affected by many factors. Therefore, we created a graphic model that could predict the prognosis of surgically treate...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13063
更新日期:2019-05-01 00:00:00
abstract:BACKGROUND:The important role of angiogenesis displaying in tumor development and metastasis has been generally realized. Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and endostatin (ES) are critical members of angiogenesis modulating the balance between pro-angiogenenic and anti-ang...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12202
更新日期:2015-07-01 00:00:00